Online inquiry

IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13837MR)

This product GTTS-WQ13837MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13837MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1496MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ7005MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ14011MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ12236MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ15437MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ7365MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ6228MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ7416MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW